
UK NEQAS

Blood Transfusion Laboratory Practice



Antibody
Identification
UI:

What, When, How, Why?

Richard Haggas & Katy Veale


UK NEQAS BTLP

Summary

- How good are we at antibody identification
- What are the key BSH rules for antibody identification
- Tips on identification
- What happens in a UK NEQAS exercise when you cannot complete ID
 - The UI process
 - How to submit a UI
 - Assessment of a UI
 - Scoring of Uls



How good are we at antibody ID



International Quality Expertise

BSH Guidelines on ABID

- When a positive antibody screen is obtained an investigation must be undertaken to determine the specificity, and the likely clinical significance
- If the patient is known to have already formed a red cell antibody, each new sample should be fully tested to exclude the presence of further alloantibodies
- The patient's plasma must be tested against an identification panel of reagent red cells which must include an IAT Panel



Inclusion of a specificity

- Antibody specificity should only be assigned when the plasma is reactive
 with at least two examples of reagent red cells expressing the antigen
 and non-reactive with at least two examples of reagent red cells lacking
 the antigen
- When one antibody specificity has been identified, the presence of additional specificities must be excluded
- Failure to recognise all of the antibody specificities within a sample may lead to a haemolytic transfusion reaction (SHOT, 1996-2010).



Excluding a specificity

- In particular, the presence of anti-c, anti-Jk^a, anti-Jk^b, anti-S, anti-s, anti-Fy^a, and anti-Fy^b should be excluded using red cells having homozygous expression of the relevant antigen.
- A single example only of each phenotype is sufficient for exclusion.
- It is acceptable to exclude Rh antibodies using validated techniques incorporating enzyme treated cells, clinically significant antibodies in other blood group systems must be excluded using IAT



Techniques and Technology

- Different technologies are better at detecting some specificities
 - E.g Capture-R does not detect IgM antibodies
- Enzyme techniques can help with ID of weak antibodies and antibody mixtures
- Know which specificities are denatured by enzymes
 - Anti-Fya / Fyb, anti-S (usually), anti-s, anti-M, anti-N



Enzymes

- Not all antibodies work in enzyme techniques
- Don't fully believe those charts we have in our labs
- Standard 2-stage enzyme panel (saline enzyme technique) may not detect all examples of anti-K or anti-Jk^a
- Enzyme IAT will detect those antibodies, but not usually a validated technique and not all technologies work using enzyme IAT



Tips on identification

- Have a means to record what you know you have included / excluded
 - E.g. Checklist

		Hom							Hom	Hom	Hom	Hom	Hom	Hom				not compulsory	not compulsory	not compulsory
D	С	С	Е	е	K	k	М	N	S	S	Fya	Fy ^b	Jka	Jkb	Lea	Leb	P ₁	Cw	Kpa	Lua

Perform a phenotype – this can also help with exclusion



Tips on identification

- Make sure all positive reactions are accounted for
- Remember to check the reactions in the antibody screen
- Remember some antibodies will have similar patterns
 - Anti-S and anti-M (linkage disequilibrium in MNS system)
- Antibody ID gets easier the more you do it
 - Practice write out panels for your colleagues
 - Encourage your lab manager to take out a TACT subscription



UI

Un Identifiable



UI - Why?

- Can't complete an antibody ID
 - Would probably refer
- We assess your ABID process
- Is it safe
- According to BSH Guidance



UI - When?

- If can't positively ID the antibodies to satisfaction
- Not sure what clinically significant antibody(s) are there
- Can't exclude clinically significant antibodies

A lot if a mixture of antibodies

Maximum 2 antibodies



UI - When not to?

- Don't need a Ul if:
- Positively identified 2 antibodies
- Can't exclude non-clin sig
 - -e.g. C^w, Lu^a, Kp^a
 - -Not available to tick



UI - When not to?

Antibody specificities (currently a maximum		Positively identified		Cannot exclude
□ C □ C □ C+/-E □ E □ e+/-C □ C ^w □ M □ N □ S □ S □ P ₁ □ Lu ^a 1 UI = Unable to interpret	 K k Kp^a Le^a Le^b Fy^a Fy^b Jk^a Jk^b Wr^a Enz non-specific ✓ UI ¹ 	c+/-E UI	□ D □ S □ C □ K □ C+/-E □ Fy ^a □ E	M S Fyb
Please note that if you have positively identified 2 s submission as UK NEQAS samples currently do no a single specificity for the purposes of EQA, as is a	t contain more than two. Anti-c+/-E is counted as		You may indicate commonly encountered antibodies of potential clinical significance that cannot be positively identified but might be present (cannot be excluded) based on your testing and the phenotype provided.	



UI - How 1

		s positively identified m of 2 in any sample)	Positively identified	
¹ UI = Unable to int Please note that if yo	ou have positively identified 2	K Kpa Lea Leb Fya Fyb Jka Jkb Wra Enz non-specific UI 1 specificities there is no need to make a UI of contain more than two. Anti-c+/-E is counted as	c+/-E	
	r the purposes of EQA, as is a			



UI – How 2


www.ukneqash.org says

Please remember to make a UI submission in the following section. See Antibody Identification Notes for more information

ОК



UI – How 3





UI - How 4


	Upload date & time	Description
PTT 'E' Exercise blank data sheet	15-07-2021 10:42	PTT 'E' Exercise blank data sheet
PTT 'R' Exercise blank data sheet	15-07-2021 10:43	PTT 'R' Exercise blank data sheet
nstructions		
nstructions	Upload date & time	Description
nstructions UI Portal Instructions	Upload date & time 23-04-2018 13:53	Description UI Portal Instructions
nstructions UI Portal Instructions Web data entry instructions		MANAGE CO.



UI – How 5

	ficities positively identified ximum of 2 in any sample)	Positively identified	Specificities that cannot be excluded	Cannot exclude
D C C C+/-E E e+/-C CW M N S S P ₁ Lu ^a	 K k Kp^a Le^a Le^b Fy^a Fy^b Jk^a Jk^b Wr^a Enz non-specific ✓ UI 1 	c+/-E UI	□ D □ S □ C □ K □ c+/-E □ Fy ^a □ E □ Fy ^b □ e+/-C □ Jk ^a □ M □ Jk ^b □ S	
Please note that if you have positively iden submission as UK NEQAS samples curren a single specificity for the purposes of EQA	tified 2 specificities there is no need to make a UI tly do not contain more than two. Anti-c+/-E is counted as A as is anti-e+/-C		You may indicate commonly encountered antibodies of potential clinical significance that cannot be positively identified but might be present (cannot be excluded) based on your testing and the phenoty.	t
	UI S	ubmission	UI Instru	tions
Upload Document	Explain briefly why identification could not be	confirmed in-ho	use, including reasons why specificities could not be positively identified or ex	ccluded.
All screen profiles including re All panel profiles including resi				
All panel profiles including resi				

UI - How 6



Positively ID'd anti-c

Other positive reaction, could be anti-K, anti-Fy^b, anti-M, anti-S – please tick the ones that can't be excluded Suspect anti-K, but can't positively identify anti-K as only one c- K+ cell available

Can't exclude anti-M as no c- M+N- cells

Can't exclude anti-Fy^b as no c- Fy(a-b+) cells

Can't exclude anti-S as no c-S+s-cells



UI – What we do with them

- Look at uploads
- Log them in a spreadsheet
- Check if have actually ticked UI at submission
- Two people check
- Agree / disagree with you
- Agree / disagree with ourselves
- Amend to UI acceptable = 0 points
- Write a letter = 40 or 50 points



UI – Example 1

Actual Response	-	Excluded Response	•	Designated Response	-
c+/-E,UI	M,K			c+/-E,K	

Patient 1

Explain briefly why identification could not be confirmed inhouse, including reasons why specificities could not be positively identified or excluded.


Unable to distinguish between Anti-K and anti-M with screen and panel in the presence of anti-c. Would refer sample to reference laboratory and provide K-c-M-units whilst awaiting report. Unable to exclude either antibody using phenotype. Also attached incomplete antigram for NHSBT panel but not performed as would not aid in differentiating between anti-K and anti-M in the presence of anti-c.



UI - Example 1

R1WR1 500749														1						6	CIUI	god O	عمام	inch	gu		Ü	011	ale hi-	4		ANTIGRAM® Antig	en Pio	me	•	
RINFI S00749							Rŀ	n-hr						K	ELL			D	UFFY	ŀ	מכו	Sex Links	d LE	wis		M	NS		Р	Li	THERA	Special Antigen Typing			Tes	st Resu
R1R1 503106 + + 0 0 0 + 0 0 0 / 0 + 0 + 0 + 0 + 0 +	#	Rh-hr	Donor Number	9	9	(E)	6) 6	10	20	V	K) 1	Kp	a) Kp	Js	a Joh	Fy	FA	Úk	JIK	Xg	Le	Let	8	8	W	X	P/1		الما وا		Cell#	I		E
R2R2 503107 + 0 + + + 0 0 0 0 / 0 + 0 + / + + + + +		R1wR1	500749	0	0	0	0	1	0	€) /	0	€	0	0	1	0	0	0	+	/+	€	0.	0	0	0	0	(D)	(D)	C	€		1	0		0
Ror 503108 + 0 0 + + + 0 / 0 + 0 + / + 0 + 0 + 0 +		R1R1	503106	+	+	0	0	+	0	0	1	0	+	0	+	1	+	0	0	0	0	+	0	0	3	0	0	+	0	0) +		2	0		0
r'r 503109 0 + 0 + + + 0 / 0 + 0 + / + + 0 / 0 + 0 +		R2R2	503107	+	0	+	+	0	0	0	1	0	+	0	+	- 1	+	+	+	+	0	0	0	0	0	+	0	+	+	C	+		3	3		3
T"r 502593 0 0 + + + + + 0 / 0 + 0 + / + 0 + 0 + 0		Ror	503108	+	0	0	+	+	+	. 0	1	0	+	0	+	1	+	0	+	0	+	0	0	+	0	+	0	+	0	C) +		4	3		3
rr 503110 0 0 0 + + + 0 / + + 0 / + + 0 + 0 + 0		r'r.	503109	0	+	0	+	+	+	0	1	0	+	0	+	1	+	+	+	+	+	+	0	÷	+	+	0	+	+	0) +	@	5	3		3
rr 502504 0 0 0 0 + + + 0 / 0 + + + 1 / + + 0 + 0 + 0 + 0 + 0 + 0 + 0 + 0 + 0		r"r	502593	0	0	+	+	+	+	0	1	0	+	0	+	1	+	0	+	0	+	0	+	0	0	+	+	+	+	C) +	@	6	3		3
rr 503111 0 0 0 + + + + 0 / 0 + + + 0 + 0 + 0 + 0			503110	0	0	0	+	+	+	0	1	+	+	Õ	+	1	+	0	+	+	0	+	0	+	0	+	+	+	+	C	+	@	7	3		3
rr 503112 0 0 0 + + + 0 / 0 + 0 + / + + 0 0 0 + + + 0 + 0		CONTRACTOR OF THE PARTY OF THE	502504	0	0	0	+	+	+	0	1	0	+	+	+	1	+	+	0	+	0	+	0	+	+	+	+	+	+	C	+		8	3		3
R1R1 503113 + + 0 0 + 0 0 / + + 0 0 + / + 0 + + + +		rr	503111	0	0	0	+	+	+	0	1	0	+	0	+	1	+	0	+	+	+	+	+	0	+	0	+	0	+	T	+		9	3		. 3
Patient Cells Patient Cells		rr	503112	0	0	0	+.	+	+	0	1	0	+	0	+	1	+	+	0	0	+	+	0	+	0	+	0	+	+	0) +	HLA+	10	3		3
Cells Mode of Rh-hr KELL DUFFY KIDD Sex LEWIS MINS P LUTHERAN Antigen Typing Test Results		R1R1	503113	+	+	0	0	+	0	0	1	+	+	0	+	1	+	0	+	+	+	+	0	+	0	+	+	0	+	C) +		11	3		0
Cell# Rh-hr Number D C E c e f Cw V K k kpa kpb Jsa Jsb Fya Fyb Jka Jkb Xga Lea Leb S s M N P1 Lua Lub Cell# Cel																						la d				3,000								0		
Cell# Rh-hr Donor D C E c e f Cw V K k Kpa Kpb Jsa Jsb Fya Fyb Jka Jkb Xga Lea Leb S s M N P1 Lua Lub Cell# 1 R1wR1 500097 + + 0 0 + 0 + 0 + 0 + +	/lod	e of				Carrie S		North No.	Rh	n-hr	4	nit lake				KELL			DU	FFY	K	IDD	Sex	LE	wis	analy.	MN	s	P	LU	THERAN		Historican	, Te	est Re	sults
1 RIWRI 500097 + + 0 0 + 0 + / + + 0 + / + + + + + + +		Се	II# Rh-hr	. D	onor	D	С	Е	С	е	f	Cw	v	K	k K	pa K	ob Js	a Js	Fya	Fyb	Jka	Jkb		1	T	S	S	М		_		3, 3,	Cell#			
			R1wR	1 50	00097	+	+	0	0	+	0	+	/	+ -	+ () 4	. /	+	+	+	+	0	+	+	0	0	+	+ -	+	+	0		13			

UI – Example 2



 "From the results obtained and additional cells available, it is possible to identify anti-c+/-E and anti-K and exclude all other common specificities and therefore your results remain as anti-c+/-E and UI."

International Quality Expertise

UIS

- We want to agree with you
- We don't always agree with ourselves
- Give us an explanation
- Give us your antigrams
- Are you following BSH guidance
- You can always appeal



Any Questions?

Feedback Feedback Feedback BTLP@ukneqas.org.uk

